Skip to Main Content

Good morning, everyone, and how are you today? We are just fine, thank you, especially now that things have quieted down around the Pharmalot campus, where the only sounds to be heard are the gentle snoring of the official mascots and the whistling of the official coffee kettle. This is, of course, a signal to get cracking. So on that note, time to pass along some tidbits to help you on your own way. Have a smashing day and do keep us in mind for secret stuff …

Pfizer chief executive Ian Read says he will not change his view toward drug pricing or alter when prices are raised, Reuters reports. His remarks contrast commitments made by three other big drug makers — Allergan, Novo Nordisk, and AbbVie — to cap most price hikes at single-digit increases just once a year. “I believe we have always priced responsibly, so I don’t need to make that commitment,” he said. Last June, Pfizer raised list prices in the US by an average of 8.8 percent, the second time in several months the drug maker substantially boosted prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.